Clinical Trials Logo
  1. Home
  2. Helicobacter Infection
  3. NCT01723059

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Helicobacter Infection Clinical Trial

Official title:
Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection

Clinical Trial Summary

Traditionally, H pylori infection has been treated with conventional triple therapy. This includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days. In Europe, the guidelines now advocate treatment of H pylori with sequential therapy which is 5 days of amoxicillin therapy with proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and proton pump inhibitor with better response rates. We hypothesize that H. pylori resistance pattern and treatment response rates observed in Europe will not be predictive of resistance patterns and response rates in the United States.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01723059
Study type Interventional
Source Dallas VA Medical Center
Contact Byron Cryer, MD
Phone 214-857-1603
Email byron.cryer@utsouthwestern.edu
Status Recruiting
Phase N/A
Start date February 2012
Completion date January 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02711176 - Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Phase 4
Completed NCT00656968 - Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Phase 4
Completed NCT00841854 - Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication Phase 4
Completed NCT02051348 - Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion Phase 2/Phase 3
Completed NCT02349685 - The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori N/A
Recruiting NCT02373280 - The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection N/A
Terminated NCT02359331 - The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection N/A
Completed NCT01163435 - Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication Phase 4